Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full-year 2025 financial results announced March 9, 2026.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results announced March 9, 2026
- Full detail in Exhibit 99.1 press release: key figures, guidance, and commentary found there
- SPRY is a commercial-stage pharma; results reflect NEFFY (epinephrine nasal spray) launch trajectory
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation filed March 9, 2026, available on company website and as Exhibit 99.2
- Reg FD disclosure ensures all investors receive simultaneous access to the same corporate messaging
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.